Guerbet SA
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solut… Read more
Guerbet SA (4G8) - Net Assets
Latest net assets as of December 2024: €391.57 Million EUR
Based on the latest financial reports, Guerbet SA (4G8) has net assets worth €391.57 Million EUR as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.04 Billion) and total liabilities (€645.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €391.57 Million |
| % of Total Assets | 37.75% |
| Annual Growth Rate | 4.62% |
| 5-Year Change | 7.48% |
| 10-Year Change | 38.64% |
| Growth Volatility | 6.16 |
Guerbet SA - Net Assets Trend (2013–2024)
This chart illustrates how Guerbet SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guerbet SA (2013–2024)
The table below shows the annual net assets of Guerbet SA from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €391.57 Million | +3.52% |
| 2023-12-31 | €378.27 Million | -0.34% |
| 2022-12-31 | €379.57 Million | -6.30% |
| 2021-12-31 | €405.09 Million | +11.20% |
| 2020-12-31 | €364.31 Million | -6.39% |
| 2019-12-31 | €389.19 Million | +6.12% |
| 2018-12-31 | €366.76 Million | +7.20% |
| 2017-12-31 | €342.14 Million | +8.69% |
| 2016-12-31 | €314.80 Million | +11.46% |
| 2015-12-31 | €282.44 Million | +9.01% |
| 2014-12-31 | €259.10 Million | +8.75% |
| 2013-12-31 | €238.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guerbet SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 79.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €16.08 Million | 4.08% |
| Other Components | €378.15 Million | 95.92% |
| Total Equity | €394.24 Million | 100.00% |
Guerbet SA Competitors by Market Cap
The table below lists competitors of Guerbet SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ratchaphruek Hospital Public Company Limited
BK:RPH
|
$44.77 Million |
|
Elanor Investors Group
AU:ENN
|
$44.81 Million |
|
8098
TWO:8098
|
$44.81 Million |
|
IMSNF
PINK:IMSNF
|
$44.86 Million |
|
Holiday Entertainment Co Ltd
TW:9943
|
$44.75 Million |
|
Yulon Nissan Motor Co Ltd
TW:2227
|
$44.73 Million |
|
Sugentech Inc
KQ:253840
|
$44.73 Million |
|
Lingotes
MC:LGT
|
$44.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guerbet SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 378,332,000 to 394,236,000, a change of 15,904,000 (4.2%).
- Net income of 16,084,000 contributed positively to equity growth.
- Dividend payments of 6,305,000 reduced retained earnings.
- Other factors increased equity by 6,125,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €16.08 Million | +4.08% |
| Dividends Paid | €6.30 Million | -1.6% |
| Other Changes | €6.12 Million | +1.55% |
| Total Change | €- | 4.20% |
Book Value vs Market Value Analysis
This analysis compares Guerbet SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €27.28 | €8.32 | x |
| 2018-12-31 | €29.28 | €8.32 | x |
| 2019-12-31 | €30.93 | €8.32 | x |
| 2020-12-31 | €28.93 | €8.32 | x |
| 2021-12-31 | €32.08 | €8.32 | x |
| 2022-12-31 | €30.08 | €8.32 | x |
| 2023-12-31 | €30.08 | €8.32 | x |
| 2024-12-31 | €31.28 | €8.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guerbet SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.89%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 2.63x
- Recent ROE (4.08%) is below the historical average (7.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 8.60% | 5.25% | 0.85x | 1.93x | €-3.34 Million |
| 2014 | 10.08% | 6.38% | 0.86x | 1.84x | €216.60K |
| 2015 | 13.89% | 8.01% | 0.54x | 3.20x | €10.99 Million |
| 2016 | 9.19% | 3.73% | 0.76x | 3.27x | €-2.55 Million |
| 2017 | 13.51% | 5.72% | 0.85x | 2.79x | €12.00 Million |
| 2018 | 12.77% | 5.89% | 0.74x | 2.95x | €10.14 Million |
| 2019 | 9.59% | 4.56% | 0.81x | 2.59x | €-1.59 Million |
| 2020 | 4.86% | 2.47% | 0.76x | 2.60x | €-18.72 Million |
| 2021 | 8.06% | 4.43% | 0.74x | 2.47x | €-7.87 Million |
| 2022 | -10.83% | -5.34% | 0.82x | 2.48x | €-79.07 Million |
| 2023 | 6.31% | 3.00% | 0.78x | 2.71x | €-13.97 Million |
| 2024 | 4.08% | 1.89% | 0.82x | 2.63x | €-23.34 Million |
Industry Comparison
This section compares Guerbet SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $243,124,770
- Average return on equity (ROE) among peers: -84.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guerbet SA (4G8) | €391.57 Million | 8.60% | 1.65x | $44.77 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |